CME

Host: Professor Sir John Hardy

This series of micro-episodes will provide important information on slowing progression in mild cognitive impairment and early Alzheimer’s disease. Drs. Marwan Sabbagh and John Hardy discuss best practices for recognizing early symptoms, diagnosis, and treatment of mild cognitive impairment and early Alzheimer’s disease.

Host: Marwan Noel Sabbagh, MD, FAAN, FANA

This series of micro-episodes will provide important information on slowing progression in mild cognitive impairment and early Alzheimer’s disease. Drs. Marwan Sabbagh and John Hardy discuss best practices for recognizing early symptoms, diagnosis, and treatment of mild cognitive impairment and early Alzheimer’s disease.

Host: Professor Sir John Hardy

This series of micro-episodes will provide important information on slowing progression in mild cognitive impairment and early Alzheimer’s disease. Drs. Marwan Sabbagh and John Hardy discuss best practices for recognizing early symptoms, diagnosis, and treatment of mild cognitive impairment and early Alzheimer’s disease.

Host: Marwan Noel Sabbagh, MD, FAAN, FANA

This series of micro-episodes will provide important information on slowing progression in mild cognitive impairment and early Alzheimer’s disease. Drs. Marwan Sabbagh and John Hardy discuss best practices for recognizing early symptoms, diagnosis, and treatment of mild cognitive impairment and early Alzheimer’s disease.

Host: Professor Sir John Hardy

This series of micro-episodes will provide important information on slowing progression in mild cognitive impairment and early Alzheimer’s disease. Drs. Marwan Sabbagh and John Hardy discuss best practices for recognizing early symptoms, diagnosis, and treatment of mild cognitive impairment and early Alzheimer’s disease.

Host: Professor Sir John Hardy

This series of micro-episodes will provide important information on slowing progression in mild cognitive impairment and early Alzheimer’s disease. Drs. Marwan Sabbagh and John Hardy discuss best practices for recognizing early symptoms, diagnosis, and treatment of mild cognitive impairment and early Alzheimer’s disease.

Host: Marwan Noel Sabbagh, MD, FAAN, FANA

This series of micro-episodes will provide important information on slowing progression in mild cognitive impairment and early Alzheimer’s disease. Drs. Marwan Sabbagh and John Hardy discuss best practices for recognizing early symptoms, diagnosis, and treatment of mild cognitive impairment and early Alzheimer’s disease.

Host: Matthew S. Davids, MD, MMSc

Although covalent Bruton's tyrosine kinase (BTK) inhibitors have proven to be effective in treating chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL) or mantle cell lymphoma (MCL), patients still experience poor outcomes after treatment failure or intolerance, necessitating new therapeutic options. Next-generation non-covalent, reversible BTK inhibitors, which have increased specificity and a novel mechanism of action, may address unmet needs and deliver better care. These next-generation BTK inhibitors have been successful in clinical trials and are changing the treatment paradigm as well as practice guidelines. Understanding key differences between the covalent and non-covalent BTK inhibitors, along with recent clinical trial data, will allow the clinical care team to introduce and integrate newly approved practice-altering therapies into current treatment plans to best meet the needs of their diverse patients with CLL/SLL or MCL.

In this educational activity, the expert faculty Chairperson will review the latest clinical evidence supporting the efficacy, safety, and tolerability of reversible, non-covalent BTK inhibitors to enhance incorporation into evidence-driven treatment sequencing for patients with CLL/SLL and MCL. The Chairperson will present a summary of the most relevant and timely advances with non-covalent BTK inhibitors while layering in their own personal, expert perspectives on how community care teams can …

Guest: Marwan Noel Sabbagh, MD, FAAN, FANA

Autophagy through sigma-1 receptor activation is a novel mechanism of action (MOA) in development for the treatment of Alzheimer’s disease. Join Dr. Marwan Noel Sabbagh as he breaks down this new MOA and recent clinical trial data.

Host: Joshua E. Reuss, MD

Alterations in ERBB2, the gene encoding HER2, have been recognized as drivers in the development of NSCLC. Therefore, HER2 is an actionable biomarker that has emerged in NSCLC diagnosis and treatment. HER2 mutations activate the HER2 signaling pathway, which facilitates oncogenic transformation and increases tumor proliferation. Although practice guidelines recommend molecular testing to identify alterations, the interpretation of tests and application of testing results to treatment decisions remain areas of educational need. Despite HER2 testing and targeted therapies changing the treatment practices for other solid tumors, the previous standard of care for NSCLC has resulted in persistently low 5-year survival rates in contrast to the high rates of survival for breast cancer. However, successful targeting of HER2-activating mutations in advanced NSCLC has now been achieved through the use of antibody-drug conjugates (ADCs) such as trastuzumab deruxtecan (T-DXd). By effectively targeting HER2-activating mutations, ADCs have emerged as a promising treatment approach for advanced NSCLC.

In this educational activity, the expert faculty Chairperson will summarize relevant and timely information on NSCLC with HER2-mutant or overexpressing alterations and highlight the use of HER2-directed ADCs in NSCLC. The Chairperson will also provide their perspectives on the top key takeaways and why they are …